European Investment Fund and cancer research charity launch new £50m fund
This article was originally published in Scrip
Cancer Research Technology (CRT), the corporate arm of the charity Cancer Research UK, and the European Investment Fund (EIF) have joined together to create a £50 million investment fund aimed at bridging the gap between cancer drug discovery and early clinical development in the UK.
You may also be interested in...
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.